Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $26.01, but opened at $27.30. LENZ Therapeutics shares last traded at $25.51, with a volume of 6,991 shares changing hands.
Analyst Ratings Changes
Several analysts have recently issued reports on LENZ shares. TD Cowen assumed coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective on the stock. Citigroup increased their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $41.67.
View Our Latest Research Report on LENZ
LENZ Therapeutics Stock Performance
The firm has a 50-day moving average price of $24.54 and a two-hundred day moving average price of $27.29. The firm has a market cap of $533.20 million, a price-to-earnings ratio of -4.04 and a beta of 0.43.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Research analysts anticipate that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.
Hedge Funds Weigh In On LENZ Therapeutics
Several large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of LENZ Therapeutics in the 4th quarter valued at about $29,000. KLP Kapitalforvaltning AS purchased a new position in LENZ Therapeutics in the 4th quarter valued at $46,000. Tower Research Capital LLC TRC lifted its stake in shares of LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after acquiring an additional 1,151 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of LENZ Therapeutics in the fourth quarter valued at about $67,000. Finally, SG Americas Securities LLC increased its stake in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after acquiring an additional 935 shares during the period. Institutional investors and hedge funds own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
